2.45
+0.01(+0.41%)
Currency In USD
| Previous Close | 2.44 |
| Open | 2.42 |
| Day High | 2.52 |
| Day Low | 2.4 |
| 52-Week High | 3.07 |
| 52-Week Low | 0.36 |
| Volume | 1.79M |
| Average Volume | 6.87M |
| Market Cap | 325.19M |
| PE | -5.44 |
| EPS | -0.45 |
| Moving Average 50 Days | 2.33 |
| Moving Average 200 Days | 1.3 |
| Change | 0.01 |
If you invested $1000 in Invivyd, Inc. (IVVD) since IPO date, it would be worth $117.34 as of January 18, 2026 at a share price of $2.45. Whereas If you bought $1000 worth of Invivyd, Inc. (IVVD) shares 3 years ago, it would be worth $1,269.43 as of January 18, 2026 at a share price of $2.45.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
GlobeNewswire Inc.
Jan 08, 2026 12:01 PM GMT
Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarterPreliminary ending 2025 cash and cash equivalents of $226.7 million after raising over $200 mil
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
GlobeNewswire Inc.
Dec 23, 2025 12:05 PM GMT
NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an investigational vaccine-alternative monoclonal anti
Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
GlobeNewswire Inc.
Dec 23, 2025 12:01 PM GMT
DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID versus placebo, at three months, from a single intramuscular (IM) dose, with protection beyond three mon